Vivos Therapeutics (VVOS) announced that its VidaSleep oral appliance, featuring Vivos’ patented and U.S. Food and Drug Administration, FDA, cleared Unilateral Bite Block technology, has been approved by the Centers for Medicare & Medicaid Services, CMS, Pricing, Data Analysis and Coding, PDAC, contractor for the treatment of mild to moderate OSA and snoring in adults.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VVOS:
- Vivos announces results published of OSA using Daytime-Nighttime Appliance
- Vivos Therapeutics Acquires The Sleep Center of Nevada
- Vivos Therapeutics completes acquisition of SCN for $6M in cash, $1.5M in stock
- Vivos Therapeutics Secures $1.1M Convertible Note
- Vivos Therapeutics downgraded to Neutral from Buy at Alliance Global Partners